- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02947243
Decreasing REcurrent Pain and Anxiety in Medical Procedures With a Pediatric Population: Trial (DREAM-T)
Study Overview
Status
Intervention / Treatment
Detailed Description
BACKGROUND:
Burn injuries are the leading cause of morbidity and mortality in children. They are associated with a lot of pain that is difficult to treat and can impede recovery, cause high levels of anxiety and alter future pain behaviors, resulting at times in chronic pain, paresthesia, or depression. Pain can also decrease participation in treatments such as physiotherapy resulting in poor health outcomes. Beyond the immediate pain experience, children may develop memories that are accurate, positively or negatively estimated (i.e., remembering more or less pain, respectively, as compared to initial pain reports). The way that children's memories are framed is important for future pain coping and distress at subsequent painful experiences. Moreover, it has been shown that pharmacological and non-pharmacological pain management strategies may buffer children from developing such biases in pain memories. Procedural pain is still largely managed pharmacologically mostly through the use of opioids, benzodiazepines and other pharmacological agents which cause a lot of side effects and do not always provide sufficient pain reduction. In recent years, the effectiveness of multimodal approaches combining medication with non-pharmacological interventions for procedural pain relief has been highlighted. Distraction techniques engaging multiple senses may grab the child's attention more than the techniques that only engage one sense (e.g, music), hence, the increasing interest in more immersive and interactive methods of distraction such as VR.
VR is an active distraction method that allows the user to interact with an immersive environment generated by a computer stimulating different senses. A review of studies on VR, mostly conducted with adult burn patients, showed a 35 to 50% reduction in procedural pain while using VR. However, despite promising results, the use of VR in healthcare settings has been limited, mainly due to its high cost. Reviews have highlighted the need for more research but mostly for the development of more portable, less expensive and more developed VR systems that would promote pain reduction during burn procedures especially for children with burn injuries who are considered one of the most challenging burn populations. However, there has been a breakthrough in technology since 2014 when big scale companies started investing in VR development for commercial gaming. Facebook purchased the Oculus Rift® for mass production allowing access to the latest technology in VR at a relatively low cost. Oculus Rift® is a VR tool that provides a wide field of view, high resolution display, integrated 3D audio and motion detection. In addition, its highly immersive properties could help achieve more analgesia compared to other VR techniques as a review has shown that the sense of presence influences the effectiveness of VR-based analgesia. The sense of presence is a subjective psychological state of consciousness of being in the virtual world whereas immersiveness refers to the physical environment that could be quantified by measuring the field of view or the peripheral vision in the VR goggles. The availability of inexpensive yet highly immersive VR googles such as Oculus Rift® could increase the use of VR in pain management and burn settings while significantly improving its cost effectiveness. A single case study assessed the feasibility of a VR intervention via Oculus Rift® in one child of 11 years old with burn injuries during occupational therapy. The study showed a reduction in pain intensity and pain unpleasantness experienced by the patient, without any side effects. To the knowledge of the investigators, no other studies have tested the distraction via Oculus Rift® for procedural pain management in children with burn injuries undergoing painful physiotherapy treatments.
AIM:
The aim of this study is to assess the effect of distraction by VR via Oculus Rift® for the relief of procedural pain, anxiety and decrease memory of pain in children with burn injuries.
Primary Research Question: In children aged 7 to 18 years, who have suffered burn injuries, does VR distraction via Oculus Rift® combined with analgesics provide better pain relief during painful procedures including dressing changes and physiotherapy than standard pharmacological treatment alone?
Secondary Research Questions: a) In children aged 7 to 18 years, who have suffered burn injuries, does VR distraction via Oculus Rift® combined with analgesics provide better anxiety relief during dressing change and physiotherapy than standard pharmacological treatment alone? b) Does the use of VR distraction lead to less distressing memories of pain than standard pharmacological treatment alone? c) Does the use of VR distraction reduce the dose and side effects of analgesics used during burn wound dressing changes and physiotherapy in children?
HYPOTHESES
- VR distraction via Oculus Rift® combined with analgesics is more effective than standard treatment (analgesics alone) to manage procedural pain of children with burn injuries.
- VR distraction via Oculus Rift® combined with analgesics is more effective than standard treatment (analgesics alone) on procedural anxiety of children with burn injuries.
- VR distraction via Oculus Rift® combined with analgesics will lead to less distressing memories of pain than standard treatment (analgesics alone) in children with burn injuries
- METHODS 4.1 Design. One-group within subject/crossover study design. Given the difficulty of ensuring a single or a double-blind condition, and in order to limit the interpersonal variability between participants, each child will serve as their own control and will receive both standard and experimental treatments during the same treatment session through a randomized order.
4.2 Sample and Setting. Participants will be recruited through convenience sampling upon admission to the surgical-trauma burn unit at CHU Ste-Justine, Montreal (Qc), Canada. For a statistical power of 80%, an alpha of 0.05, and a significant difference of two points on a 0 to 10 on the NRS pain scale, the size of the total desired sample is 40 participants who will serve as their own controls. The setting of the study is the main referral center for pediatric burns in Quebec. It receives nearly 60 admissions during the time of the year when there is a higher incidence of burns (April to October) and over all close to 100 admissions per year. One third of the total admissions are aged 7 years and older. Given a possible census of 33 admissions per year, it appears feasible to recruit around 40 patients over a period of two years. This is also the reason behind the choice of the design which would be the most feasible given the total population available for recruitment.
.3 Interventions. A) Standard pharmacological treatment B) Standard treatment in addition to Virtual Reality distraction via Oculus Rift
4.4. Measures. Pain, anxiety and comfort measures will be taken before the treatment (physiotherapy or dressing change) session (T1) (for expectancy and baseline state), after the first sequence of the session (T2) and after the second sequence of the session (T3). Healthcare professionals will be asked to fill an anonymous satisfaction questionnaire 30 minutes after the end of the session (T4). Memories of pain/anxiety will be assessed at least 24 hours after each procedure (T5).
4.5 Study proceedings. Physiotherapy and dressing change sessions typically last between 10 and 20 minutes. The duration will be divided in two sequences of the same duration (5 to 10 minutes) where the participant receives the same treatment (range-of-motion exercises for physiotherapy or wound cleaning and gauzes application for dressing changes) by the same healthcare professional (physiotherapist or nurse). For one sequence, only the standard pharmacological treatment will be administered and for the other sequence, patients will receive the standard pharmacological treatment in addition to the virtual reality distraction via OR. The order of sequences will be randomized.
4.6 Data analysis plan. Multivariate Analyses and quantitative comparisons will be conducted within and between subjects for the dependent variables for repeated measures. The mean difference in pain scores of patients at each time-period will be compared using a paired t-test. Since the use of rescue medication is a potential indication of a treatment failure, the primary analysis will be supplemented by an analysis comparing the proportion of patients receiving rescue medication anytime during the procedure. Interpretation of the primary analyses will be made with reference to the data regarding rescue medication use. Data collected on dichotomous variables will be analyzed using a chi-square test and post-hoc analyses if the results are statistically significant.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C4
- CHU Ste. Justine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- suffer from a burn injury requiring wound dressing change or physiotherapy
- presence of a consenting parent who can understand, read and write either French or English
Exclusion Criteria:
- requiring intensive care
- having a diagnosed cognitive impairment
- are unconscious or intubated during dressing change or physiotherapy
- suffer from epilepsy (considering the nature of the intervention)
- allergic to opioids or other analgesics used for standard pharmacological treatment
- having burn injuries on the face preventing the use of the Oculus Rift headset
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Standard pharmacological treatment
Standard pharmacological treatment (including Morphine) according to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
|
As per unit's protocol
Other Names:
|
|
EXPERIMENTAL: VR distraction via Oculus Rift
In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention.
|
In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention.
The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz.
It has very effective 360 degree positional tracking and integrated 3D audio.
These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness.
The child, depending on the burn site, will have the opportunity to interact with the game.
Video games, approved by healthcare professionals with extensive experience in pediatrics, will be adapted for children and tailored to minimize cyber sickness.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Pain Score
Time Frame: T2: 10 minutes within the session (immediately after the first sequence of the session); T3: 20 minutes within the session (immediately after the second sequence of the session)
|
Numerical Rating Scale (NRS) ranging from 0 to 10; 0=no pain to 10=pain as bad as it could be
|
T2: 10 minutes within the session (immediately after the first sequence of the session); T3: 20 minutes within the session (immediately after the second sequence of the session)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Experience
Time Frame: T2: 10 minutes within the session (immediately after the first sequence of the session); T3: 20 minutes within the session (immediately after the second sequence of the session)
|
Graphic Rating Scale (GRS) consisting of seven items to measure the cognitive, the affective and the sensory components of pain
|
T2: 10 minutes within the session (immediately after the first sequence of the session); T3: 20 minutes within the session (immediately after the second sequence of the session)
|
|
Expected Anxiety
Time Frame: Baseline (T1)
|
Children's Fear Scale (CFS)
|
Baseline (T1)
|
|
Experienced Anxiety
Time Frame: T2: 10 minutes within the session (immediately after the first sequence of the session); T3: 20 minutes within the session (immediately after the second sequence of the session)
|
Children's Fear Scale (CFS)
|
T2: 10 minutes within the session (immediately after the first sequence of the session); T3: 20 minutes within the session (immediately after the second sequence of the session)
|
|
Comfort Level
Time Frame: T2: 10 minutes within the session (immediately after the first sequence of the session); T3: 20 minutes within the session (immediately after the second sequence of the session)
|
Behavioural observation scale of comfort level for child burn victims (OCCEB-BECCO)
|
T2: 10 minutes within the session (immediately after the first sequence of the session); T3: 20 minutes within the session (immediately after the second sequence of the session)
|
|
Pain Memory
Time Frame: 24 hours after the procedure (T5)
|
A measure of the child's memory of pain using the same measure (NRS) administered during the initial data collection to assess this construct
|
24 hours after the procedure (T5)
|
|
Anxiety Memory
Time Frame: 24 hours after the procedure (T5)
|
A measure of the child's memory of anxiety using the same measure (CFS) administered during the initial data collection to assess this construct
|
24 hours after the procedure (T5)
|
|
Range Of Motion
Time Frame: Baseline (T1); T2: 10 minutes within the session (immediately after the first sequence of the session); T3: 20 minutes within the session (immediately after the second sequence of the session)
|
(only for physiotherapy sessions) Using a goniometer
|
Baseline (T1); T2: 10 minutes within the session (immediately after the first sequence of the session); T3: 20 minutes within the session (immediately after the second sequence of the session)
|
|
Satisfaction Level
Time Frame: T4: 30 minutes after the procedure
|
Satisfaction questionnaire developed by the team
|
T4: 30 minutes after the procedure
|
|
Side Effects
Time Frame: T4: 30 minutes after the procedure
|
Nausea, vertigo or other side effects related to the use of Oculus Rift
|
T4: 30 minutes after the procedure
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Anxiety
- Pain management
- Physical therapy
- Physiotherapy
- Virtual reality
- Acute pain
- Burns
- Clinical Research
- Procedural pain
- Procedural anxiety
- Young children
- Dressing change
- Burn injuries
- Virtual environment
- Immersive distraction
- Virtual world
- Children, Child
- Kid, Kids
- Pediatric, Pediatrics
- Nursing Practice
- Oculus rift
- Burn unit
- Burn dressing
- Non-pharmacological, nonpharmacological
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-1383
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
Boston Scientific CorporationRecruitingLow Back Pain | Chronic Pain | Chronic Low-back Pain | Leg Pain | Intractable Pain | Chronic Leg PainUnited States
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Qi's ClinicNot yet recruitingNon-Cancer Pain,Musculoskeletal Pain,Chronic Pain,Acute Pain
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
noiVita SrlsUniversity of Eastern PiedmontCompletedCervical Pain | Pain Management | Lumbar Pain | Muscular | Chronic Pain (Back / Neck)Italy
-
Chinese University of Hong KongNot yet recruitingPain, Acute | Chronic Post Operative Pain | Pain, ChronicHong Kong
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of SaskatchewanRoyal University Hospital FoundationCompletedPain | Pain, Acute | Pain, Chronic | Pain, IntractableCanada
Clinical Trials on Morphine
-
Hospital Central do FunchalRecruitingAnalgesia | Patient Satisfaction | Post Operative Pain | Cesarean Section Pain | Analgesia ObstetricalPortugal
-
Indiana UniversityCompletedNeonatal Abstinence Syndrome | Neonatal Opioid Withdrawal Syndrome | Neonatal Opioid WithdrawalUnited States
-
Universitaire Ziekenhuizen KU LeuvenActive, not recruitingAnalgesia | Nausea and Vomiting, Postoperative | Morphine | Morphine Adverse Reaction | Morphine Induced Pruritis | Spinal AnalgesiaBelgium
-
Javelin PharmaceuticalsCompletedPain, PostoperativeUnited States
-
Javelin PharmaceuticalsCompleted
-
Mahidol UniversityCompletedLung Diseases | Solitary MassThailand
-
Karlstad Central HospitalEnrolling by invitationGastreoesophageal Reflux Disease | Perioperative Pain ManagementSweden
-
University of Colorado, DenverCompletedScoliosis | Pain Management | Spinal FusionUnited States
-
Javelin PharmaceuticalsCompletedPost-Operative Pain | Third Molar Extraction
-
University of MonastirCompletedTitrated Versus High and Low Dose Nebulized Morphine to Reduce Pain in Emergency Settings (TIMORNEB)Acute Pain | Post-Traumatic HeadacheTunisia